Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07311187
Active, not recruiting Observational

Quiet Quitting, Quality of Life, and Coping Strategies Among Healthcare Workers

NCT07311187 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Ortopedico Rizzoli
Phase
Observational
Started
2025-06-03
Last updated
2026-01-02

Condition(s) studied

Well-being at Work

Investigational drug(s) / intervention(s)

Quiet Quitting Scale

Quiet Quitting Scale: The Quiet Quitting scale (QQs) will be used to assess the phenomenon of silent resignation and to identify possible prognostic factors.

Study summary

The purpose of the study is to investigate the psychological and physical well-being of healthcare professionals working at an orthopedic surgical hospital. In particular, we want to assess the presence and spread of a new work phenomenon called "quiet quitting," a phenomenon that has spread significantly in recent years in many work contexts.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * All workers in the healthcare sector, such as nurses, physical therapists, technical professionals, and social * Healthcare workers employed by the services and departments of the facilities involved. * Workers who express their willingness to participate in the study Exclusion Criteria: * Workers employed on temporary contracts or on contracts with third parties other than the hospital involved * Workers who are absent from work for more than 3 months during the survey period, such as workers on maternity leave, long-term sick leave, or accident leave.

Primary outcome measure(s)

  • Quiet Quitting scale — The Quiet Quitting Scale survey was first conducted in June 2025 and will be repeated in 2026.
    The scale consists of nine items that investigate three main aspects of the phenomenon: detachment, understood as emotional separation from work-related concerns and thoughts; lack of motivation, understood as reduced drive to actively engage in one's work; and lack of initiative, understood as a low propensity to go beyond the minimum requirements of supervisors, i.e., to engage in non-mandatory activities. Responses to each item are provided on a 5-point Likert scale ranging from 1 to 5. The overall score on the scale is reported as the average of the items, and an average score above 2.06 identifies a 'quiet quitter', i.e. a person who experiences the phenomenon of silent abandonment.

Trial sites (1)

FacilityCityRegionStatus
SAITeR IRCCS Istituto Ortopedico Rizzoli Bologna Italy

More Istituto Ortopedico Rizzoli trials in Italy

Clinical and Radiological Results of Long Term Tibial and Femoral Osteotomy in Knee Ostheoarthritis With Concomitant Lower Limb Malalignement Recruiting
Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design Recruiting
Combined Use of PRP and Hyaluronic Acid for Infiltrative Treatment of Patients With Knee Osteoarthritis Recruiting
Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas Recruiting
Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis Imperfecta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07311187 on ClinicalTrials.gov ↗ ← All trials in Italy